- Hikma Pharmaceuticals raised its outlook for its injectables and generics businesses after reporting strong sales in the first half of the year thanks to the launch of new products.

The company said it expected full-year Injectables revenue to be in the range of $870m to $900m and core operating margin to be in the range of 36% to 38%.

Generics revenue for the full year was expected to be in the range of $690m to $720m, with core operating margin in the range of 16% to 18%.

Branded revenue, meanwhile, was expected to be higher in the second half of the year and with revenue growth in constant currency to be in the mid-single digits.

The upgraded outlook comes as the company saw profits jumped on the back of an increase in revenues.

For the six months ended 30 June 2019, pre-tax profits rose to $226m from $141m a year earlier and revenue grew 8% to $1,047m, reflecting 'strong sales of our in-market products and new product launches,' the company said.

The interim dividend was raised by 17% to 14 cents per share.

Story provided by